Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Executive Chairman

Chief Strategy Officer

President and CEO

Chief Medical Officer

Chief Financial Officer

General Counsel

Chief Business Officer

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for dis...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-26	Premium	bought	Premium	Premium	Premium	-
2024-02-22	Premium	acquired	Premium	Premium	Premium	Executive Chairman
2024-02-22	Premium	acquired	Premium	Premium	Premium	Chief Strategy Officer
2024-02-05	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-05	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-02-05	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-05	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-02-05	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-02-03	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-02-03	Premium	acquired	Premium	Premium	Premium	Chief Business Officer
2024-02-03	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-02-03	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-03	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-31	Premium	sold	Premium	Premium	Premium	President and CEO
2024-01-31	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-01-31	Premium	sold	Premium	Premium	Premium	General Counsel
2024-01-31	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-31	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-14	Premium	bought	Premium	Premium	Premium	-
2023-08-30	Premium	bought	Premium	Premium	Premium	President and CEO
2023-07-10	Premium	acquired	Premium	Premium	Premium	-
2023-07-07	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-
2023-06-14	Premium	acquired	Premium	Premium	Premium	-

OCUL - Ocular Therapeutix Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for OCUL